After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Diagnostics & Research industry segment, falling under the Healthcare sector. The current market capitalization of Neogenomics Inc is $1.02B. A total of 2.02 million shares were traded on the day, compared to an average of 2.54M shares.
In the most recent transaction, Sherman Jeffrey Scott bought 20,000 shares of NEO for 5.62 per share on Aug 06 ’25. After the transaction, the Chief Financial Officer now owns 188,332 company shares. In a previous transaction on Aug 06 ’25, Zook Anthony P. bought 17,900 shares at 5.58 per share. NEO shares that Chief Executive Officer owns now total 38,066.
Among the insiders who bought shares, Kelly Michael Aaron acquired of 5,000 shares on May 27 ’25 at a per-share price of $7.60. This resulted in the Director holding 5,000 shares of NEO after the transaction. In another insider transaction, Stone Warren bought 5,700 shares at $8.58 per share on May 12 ’25. Company shares held by the Pres & Chief Operating Officer now total 108,280.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, NEO has a high of $19.11 and a low of $4.72.
As of this writing, NEO has an earnings estimate of $0.02 per share for the current quarter. EPS was calculated based on a consensus of 13.0 estimates, with a high estimate of $0.05 per share and a lower estimate of $0.01. The company reported an EPS of $0.05 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. NEO’s latest balance sheet shows that the firm has $515.39M in Cash & Short Term Investments as of fiscal 2021. There were $612.79M in debt and $87.23M in liabilities at the time. Its Book Value Per Share was $6.64, while its Total Shareholder’s Equity was $1.11B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NEO is Buy with a score of 3.81.
